Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hutchison MediPharma and Eli Lilly Sign New Discovery Deal

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Shanghai-headquartered Hutchison MediPharma signed a new partnership agreement with Eli Lilly on drug discovery and development, according to MediPharma's chief executive officer

You may also be interested in...



Eli Lilly CEO John Lechleiter Rules Out Mega-merger Or Major Push Into Generics, Outlines Strategy Aimed At China's 21st Century Rise In An Interview With PharmAsia News

Eli Lilly's chief executive officer, John Lechleiter, recently discussed with PharmAsia News' China bureau the Indianapolis-headquartered outfit's strategy to benefit from the rapid rise of China's economy and scientific capabilities while also spelling out that the company would not seek to engineer any mega-merger ahead. The organic chemist who heads Lilly suggested in a keynote talk in Shanghai that Chinese scientists would increasingly help shape "the century of human medicine" if the government strengthens the intellectual property regime in order to unleash innovation (PharmAsia News, April 02, 2010), and expanded on those ideas in a follow-up interview.

Eli Lilly CEO John Lechleiter Rules Out Mega-merger Or Major Push Into Generics, Outlines Strategy Aimed At China's 21st Century Rise In An Interview With PharmAsia News

Eli Lilly's chief executive officer, John Lechleiter, recently discussed with PharmAsia News' China bureau the Indianapolis-headquartered outfit's strategy to benefit from the rapid rise of China's economy and scientific capabilities while also spelling out that the company would not seek to engineer any mega-merger ahead. The organic chemist who heads Lilly suggested in a keynote talk in Shanghai that Chinese scientists would increasingly help shape "the century of human medicine" if the government strengthens the intellectual property regime in order to unleash innovation (PharmAsia News, April 02, 2010), and expanded on those ideas in a follow-up interview.

Lilly CEO, In Shanghai, Predicts Better Patent Protection Will Unleash Scientific Innovation Across China

SHANGHAI - Calling the start of the new millennium "the century of human medicine," John Lechleiter, Eli Lilly's chief executive officer, predicted that Chinese scientists would help shape the era, but also said that the government needs to advance its intellectual property regime in order to unleash innovation

Related Content

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel